BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 17720776)

  • 21. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development.
    Lindström S; Wiklund F; Adami HO; Bälter KA; Adolfsson J; Grönberg H
    Cancer Res; 2006 Nov; 66(22):11077-83. PubMed ID: 17108148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular changes in prostate cancer cells induced by intermittent androgen suppression.
    Laitinen S; Martikainen PM; Tammela TL; Visakorpi T
    Eur Urol; 2007 Sep; 52(3):725-32. PubMed ID: 17141945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer.
    Thomas LN; Douglas RC; Lazier CB; Gupta R; Norman RW; Murphy PR; Rittmaster RS; Too CK
    J Urol; 2008 Jan; 179(1):147-51. PubMed ID: 17997435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.
    Mitsiades N; Sung CC; Schultz N; Danila DC; He B; Eedunuri VK; Fleisher M; Sander C; Sawyers CL; Scher HI
    Cancer Res; 2012 Dec; 72(23):6142-52. PubMed ID: 22971343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
    Zhao J; Epstein JI
    Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer.
    Ryan CJ; Haqq CM; Simko J; Nonaka DF; Chan JM; Weinberg V; Small EJ; Goldfine ID
    Urol Oncol; 2007; 25(2):134-40. PubMed ID: 17349528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
    Byrns MC; Mindnich R; Duan L; Penning TM
    J Steroid Biochem Mol Biol; 2012 May; 130(1-2):7-15. PubMed ID: 22265960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-cadherin switching occurs in high Gleason grade prostate cancer.
    Jaggi M; Nazemi T; Abrahams NA; Baker JJ; Galich A; Smith LM; Balaji KC
    Prostate; 2006 Feb; 66(2):193-9. PubMed ID: 16173043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease.
    Ricciardelli C; Choong CS; Buchanan G; Vivekanandan S; Neufing P; Stahl J; Marshall VR; Horsfall DJ; Tilley WD
    Prostate; 2005 Apr; 63(1):19-28. PubMed ID: 15378523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis.
    Diallo JS; Aldejmah A; Mouhim AF; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
    BJU Int; 2008 May; 101(10):1302-9. PubMed ID: 18294307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review.
    Wang LG; Mencher SK; McCarron JP; Ferrari AC
    Oncol Rep; 2004 Jun; 11(6):1325-9. PubMed ID: 15138573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer.
    Puccetti L; Supuran CT; Fasolo PP; Conti E; Sebastiani G; Lacquaniti S; Mandras R; Milazzo MG; Dogliani N; De Giuli P; Fasolis G
    Eur Urol; 2005 Aug; 48(2):215-21; Discussion 221-3. PubMed ID: 15992991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population.
    Inoue T; Segawa T; Shiraishi T; Yoshida T; Toda Y; Yamada T; Kinukawa N; Kinoshita H; Kamoto T; Ogawa O
    Urology; 2005 Aug; 66(2):332-7. PubMed ID: 16098362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.
    Lin HK; Steckelbroeck S; Fung KM; Jones AN; Penning TM
    Steroids; 2004 Dec; 69(13-14):795-801. PubMed ID: 15582534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In situ androgen production in human gastric carcinoma--androgen synthesizing and metabolizing enzymes.
    Nakamura Y; Shimada N; Suzuki T; Imatani A; Sekine H; Ohara S; Shimosegawa T; Sasano H
    Anticancer Res; 2006; 26(3A):1935-9. PubMed ID: 16827127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical analysis of neuroendocrine differentiation in prostate cancer.
    Ishida E; Nakamura M; Shimada K; Tasaki M; Konishi N
    Pathobiology; 2009; 76(1):30-8. PubMed ID: 19188748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer.
    Takayama H; Nonomura N; Nishimura K; Oka D; Shiba M; Nakai Y; Nakayama M; Tsujimura A; Aozasa K; Okuyama A
    BJU Int; 2009 Feb; 103(4):470-4. PubMed ID: 18778349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between prostaglandin E2 receptors and clinicopathologic features in human prostate cancer tissue.
    Miyata Y; Kanda S; Maruta S; Matsuo T; Sakai H; Hayashi T; Kanetake H
    Urology; 2006 Dec; 68(6):1360-5. PubMed ID: 17169665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
    Yang Q; Titus MA; Fung KM; Lin HK
    J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
    Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
    Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.